Retrospective appraisal of busulfan dose adjustment in children

被引:25
作者
Dupuis, LL
Najdova, M
Saunders, EF
机构
[1] Hosp Sick Children, Dept Pharm, Toronto, ON M5G 1X8, Canada
[2] Hosp Sick Children, Div Haematol Oncol, Bone Marrow Transplant Program, Toronto, ON M5G 1X8, Canada
关键词
busulfan; pharmacokinetics; pediatrics; bone marrow transplant;
D O I
10.1038/sj.bmt.1702700
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
This report describes and critically appraises our experience with busulfan dose adjustment in children undergoing bone marrow transplant between April 1997 and March 1999. All children received an initial busulfan dose of 40 mg/m(2) p.o. or by nasogastric tube, Whole blood samples were obtained 1, 1.5 and 6 h later and analyzed for busulfan content by gas chromatography with electron capture detection. The area under the whole blood busulfan concentration vs time curve (AUC) and an individualized dose which would achieve an AUC of 1300 muM/min were calculated. Mean and median busulfan doses were calculated using actual, ideal and effective body weight and stratified according to age. The relationship between the busulfan concentration at hour 6 and AUC was determined using linear regression. Thirty-nine courses of busulfan were evaluated in 38 patients. A change from the initial busulfan dose was required to achieve the target AUC in 34 courses (87%). Most children >1 to 5 years old required dose increments while most children >5 years old required dose reductions, Obesity did not significantly affect busulfan dose requirements, Busulfan concentrations at 6 h only weakly predicted the AUC achieved (r(2) = 0.496; P = 0.001). Based on these findings, we recommend that the initial busulfan dose be assigned according to patient age and actual body weight. We also recommend that busulfan AUC be calculated for children using a four-sample (1, 1.5, 4 and 6 h) limited sampling technique.
引用
收藏
页码:1143 / 1147
页数:5
相关论文
共 22 条
[1]   An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease [J].
Bolinger, AM ;
Zangwill, AB ;
Slattery, JT ;
Glidden, D ;
DeSantes, K ;
Heyn, L ;
Risler, LJ ;
Bostrom, B ;
Cowan, MJ .
BONE MARROW TRANSPLANTATION, 2000, 25 (09) :925-930
[2]   An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children [J].
Chattergoon, DS ;
Saunders, EF ;
Klein, J ;
Calderwood, S ;
Doyle, J ;
Freedman, MH ;
Koren, G .
BONE MARROW TRANSPLANTATION, 1997, 20 (05) :347-354
[3]  
Dix SP, 1996, BONE MARROW TRANSPL, V17, P225
[4]   Oral syringe for extemporaneously preparing doses [J].
Dupuis, L ;
Armstrong, C .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (07) :735-735
[5]  
Gibaldi M., 1991, BIOPHARMACEUTICS CLI, P377
[6]  
Gibbs JP, 1999, DRUG METAB DISPOS, V27, P1466
[7]   The impact of obesity and disease on busulfan oral clearance in adults [J].
Gibbs, JP ;
Gooley, T ;
Corneau, B ;
Murray, G ;
Stewart, P ;
Appelbaum, FR ;
Slattery, JT .
BLOOD, 1999, 93 (12) :4436-4440
[8]  
Hassan M, 1996, BONE MARROW TRANSPL, V18, P843
[9]   PHARMACOKINETICS OF HIGH-DOSE BUSULFAN IN RELATION TO AGE AND CHRONOPHARMACOLOGY [J].
HASSAN, M ;
OBERG, G ;
BEKASSY, AN ;
ASCHAN, J ;
EHRSSON, H ;
LJUNGMAN, P ;
LONNERHOLM, G ;
SMEDMYR, B ;
TAUBE, A ;
WALLIN, I ;
SIMONSSON, B .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (02) :130-134
[10]  
HASSAN M, 1994, BLOOD, V84, P2144